Results 161 to 170 of about 113,904,810 (178)
Some of the next articles are maybe not open access.
Journal of Neuroimmune Pharmacology, 2007
Despite the success of antiretroviral therapy in controlling HIV replication, treatment failure may ultimately occur in more than 50% of the individuals on antiretroviral therapy. Cellular targets offer an attractive alternative, as it may be more difficult for HIV to develop resistance to alternative cellular inhibitory pathways.
Xu, Wang +5 more
openaire +2 more sources
Despite the success of antiretroviral therapy in controlling HIV replication, treatment failure may ultimately occur in more than 50% of the individuals on antiretroviral therapy. Cellular targets offer an attractive alternative, as it may be more difficult for HIV to develop resistance to alternative cellular inhibitory pathways.
Xu, Wang +5 more
openaire +2 more sources
Anti-Cancer Drugs, 2019
Neurokinin-1 receptor (NK1R) antagonists are known for their anxiolytic, antiemetic, anticancer, and anti-inflammatory effects. Aprepitant is used in vomiting and nausea, which are the most common side-effects of patients undergoing chemotherapy for cancer.
DİKMEN, MİRİŞ +2 more
openaire +4 more sources
Neurokinin-1 receptor (NK1R) antagonists are known for their anxiolytic, antiemetic, anticancer, and anti-inflammatory effects. Aprepitant is used in vomiting and nausea, which are the most common side-effects of patients undergoing chemotherapy for cancer.
DİKMEN, MİRİŞ +2 more
openaire +4 more sources
Journal of Obstetrics and Gynaecology Research, 2017
AbstractAimThis study was conducted to evaluate the efficacy and the difference in effects of the oral neurokinin‐1(NK‐1) receptor antagonist aprepitant for chemotherapy‐induced nausea/vomiting (CINV) in Japanese patients with gynecological cancer receiving highly emetogenic (cisplatin) and moderately emetogenic (carboplatin) chemotherapy ...
Masae Ikeda +4 more
openaire +2 more sources
AbstractAimThis study was conducted to evaluate the efficacy and the difference in effects of the oral neurokinin‐1(NK‐1) receptor antagonist aprepitant for chemotherapy‐induced nausea/vomiting (CINV) in Japanese patients with gynecological cancer receiving highly emetogenic (cisplatin) and moderately emetogenic (carboplatin) chemotherapy ...
Masae Ikeda +4 more
openaire +2 more sources
International Journal of Radiation Oncology*Biology*Physics, 2015
To assess, in a prospective, observational study, the safety and efficacy of the addition of the neurokinin-1-receptor antagonist (NK1-RA) aprepitant to concomitant radiochemotherapy, for the prophylaxis of radiation therapy-induced nausea and vomiting.This prospective observational study compared the antiemetic efficacy of an NK1-RA (aprepitant), a 5 ...
Franziska, Jahn +5 more
openaire +2 more sources
To assess, in a prospective, observational study, the safety and efficacy of the addition of the neurokinin-1-receptor antagonist (NK1-RA) aprepitant to concomitant radiochemotherapy, for the prophylaxis of radiation therapy-induced nausea and vomiting.This prospective observational study compared the antiemetic efficacy of an NK1-RA (aprepitant), a 5 ...
Franziska, Jahn +5 more
openaire +2 more sources
Liver International
AbstractBackgroundIntrahepatic cholangiocarcinoma (iCCA) has a poor prognosis and limited treatment options. Aprepitant, a selective NK‐1R antagonist, can inhibit the growth of various tumours in vitro and in vivo. However, it remains unclear whether aprepitant has cytotoxic effects on iCCA.MethodsWe measured the expression of SP/NK‐1R in clinical ...
Yang Yang +6 more
openaire +2 more sources
AbstractBackgroundIntrahepatic cholangiocarcinoma (iCCA) has a poor prognosis and limited treatment options. Aprepitant, a selective NK‐1R antagonist, can inhibit the growth of various tumours in vitro and in vivo. However, it remains unclear whether aprepitant has cytotoxic effects on iCCA.MethodsWe measured the expression of SP/NK‐1R in clinical ...
Yang Yang +6 more
openaire +2 more sources
Journal of Clinical Oncology, 2012
Purpose Aprepitant, a 5-HT3 receptor antagonist (5HT3-RA), and dexamethasone are standard antiemetic therapy for prevention of single-day, cisplatin-induced nausea and vomiting. We conducted a double-blind, placebo-controlled phase III cross-over study that compared aprepitant to placebo combined with standard antiemetic prophylaxis (a 5HT3-RA and ...
Costantine, Albany +5 more
openaire +2 more sources
Purpose Aprepitant, a 5-HT3 receptor antagonist (5HT3-RA), and dexamethasone are standard antiemetic therapy for prevention of single-day, cisplatin-induced nausea and vomiting. We conducted a double-blind, placebo-controlled phase III cross-over study that compared aprepitant to placebo combined with standard antiemetic prophylaxis (a 5HT3-RA and ...
Costantine, Albany +5 more
openaire +2 more sources
Exploring the Anti-Inflammatory Effects of Aprepitant: An Antagonist of the Neurokinin-1 Receptor
Asian Journal of Biological and Life SciencesPavithra Pavithra J +4 more
openaire +1 more source
Journal of the American Academy of Dermatology, 2012
Barry Ladizinski +2 more
openaire +1 more source
Barry Ladizinski +2 more
openaire +1 more source
Human Positron Emission Tomography Studies of Brain Neurokinin 1 Receptor Occupancy by Aprepitant
Biological Psychiatry, 2004Jarmo Hietala +2 more
exaly